company background image
AORT logo

Artivion NYSE:AORT Stock Report

Last Price

US$27.97

Market Cap

US$1.2b

7D

-5.2%

1Y

54.2%

Updated

19 Dec, 2024

Data

Company Financials +

Artivion, Inc.

NYSE:AORT Stock Report

Market Cap: US$1.2b

AORT Stock Overview

Manufactures, processes, and distributes medical devices and implantable human tissues worldwide. More details

AORT fundamental analysis
Snowflake Score
Valuation3/6
Future Growth4/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Rewards

Trading at 14.5% below our estimate of its fair value

Earnings are forecast to grow 123.9% per year

Risk Analysis

Shareholders have been diluted in the past year

Significant insider selling over the past 3 months


My Notes

Capture your thoughts, links and company narrative

Artivion, Inc. Competitors

InMode

NasdaqGS:INMD

US$1.5b

CeriBell

NasdaqGS:CBLL

US$964.4m

AtriCure

NasdaqGM:ATRC

US$1.5b

Paragon 28

NYSE:FNA

US$840.6m

Price History & Performance

Summary of share price highs, lows and changes for Artivion
Historical stock prices
Current Share PriceUS$27.97
52 Week HighUS$30.45
52 Week LowUS$16.48
Beta1.74
1 Month Change3.86%
3 Month Change10.95%
1 Year Change54.19%
3 Year Change37.44%
5 Year Change4.06%
Change since IPO599.25%

Recent News & Updates

Estimating The Fair Value Of Artivion, Inc. (NYSE:AORT)

Dec 19
Estimating The Fair Value Of Artivion, Inc. (NYSE:AORT)

Recent updates

Estimating The Fair Value Of Artivion, Inc. (NYSE:AORT)

Dec 19
Estimating The Fair Value Of Artivion, Inc. (NYSE:AORT)

When Should You Buy Artivion, Inc. (NYSE:AORT)?

Nov 07
When Should You Buy Artivion, Inc. (NYSE:AORT)?

Returns At Artivion (NYSE:AORT) Are On The Way Up

Sep 28
Returns At Artivion (NYSE:AORT) Are On The Way Up

Estimating The Intrinsic Value Of Artivion, Inc. (NYSE:AORT)

Sep 06
Estimating The Intrinsic Value Of Artivion, Inc. (NYSE:AORT)

Is Artivion (NYSE:AORT) A Risky Investment?

Jun 28
Is Artivion (NYSE:AORT) A Risky Investment?

Data-Driven Growth Fuels More Upside For Overlooked Artivion

Jun 21

Artivion's (NYSE:AORT) Returns On Capital Are Heading Higher

May 08
Artivion's (NYSE:AORT) Returns On Capital Are Heading Higher

Is Artivion (NYSE:AORT) Using Too Much Debt?

Jan 13
Is Artivion (NYSE:AORT) Using Too Much Debt?

Artivion Stock: A First Assessment

Dec 27

Investors Still Aren't Entirely Convinced By Artivion, Inc.'s (NYSE:AORT) Revenues Despite 27% Price Jump

Nov 23
Investors Still Aren't Entirely Convinced By Artivion, Inc.'s (NYSE:AORT) Revenues Despite 27% Price Jump

Artivion's Ongoing Clinical Studies Could Drive Significant Growth Starting In 2025

Oct 13

Artivion: On-X Sales Double 5-Year Average, Far More Constructive View (Rating Upgrade)

Jul 20

Artivion's (NYSE:AORT) Returns On Capital Are Heading Higher

May 10
Artivion's (NYSE:AORT) Returns On Capital Are Heading Higher

Artivion (NYSE:AORT) Has A Somewhat Strained Balance Sheet

Mar 09
Artivion (NYSE:AORT) Has A Somewhat Strained Balance Sheet

Artivion Non-GAAP EPS of $0.10 beats by $0.12, revenue of $79.4M misses by $0.77M

Feb 16

Artivion: PROACT Xa Overhang Remains Well In Situ, Reaffirm Hold

Dec 18

Artivion (NYSE:AORT) Is Making Moderate Use Of Debt

Sep 29
Artivion (NYSE:AORT) Is Making Moderate Use Of Debt

Artivion: Stopping PROACT Xa Trial Removes Long-Term Growth Driver

Sep 27

Shareholder Returns

AORTUS Medical EquipmentUS Market
7D-5.2%-3.4%-3.5%
1Y54.2%9.0%22.1%

Return vs Industry: AORT exceeded the US Medical Equipment industry which returned 11.2% over the past year.

Return vs Market: AORT exceeded the US Market which returned 24% over the past year.

Price Volatility

Is AORT's price volatile compared to industry and market?
AORT volatility
AORT Average Weekly Movement3.8%
Medical Equipment Industry Average Movement7.8%
Market Average Movement6.3%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market3.1%

Stable Share Price: AORT has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: AORT's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19841,500Pat Mackinartivion.com

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms.

Artivion, Inc. Fundamentals Summary

How do Artivion's earnings and revenue compare to its market cap?
AORT fundamental statistics
Market capUS$1.16b
Earnings (TTM)-US$842.00k
Revenue (TTM)US$384.90m

3.0x

P/S Ratio

-1,393x

P/E Ratio

Is AORT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AORT income statement (TTM)
RevenueUS$384.90m
Cost of RevenueUS$136.53m
Gross ProfitUS$248.37m
Other ExpensesUS$249.22m
Earnings-US$842.00k

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.02
Gross Margin64.53%
Net Profit Margin-0.22%
Debt/Equity Ratio103.0%

How did AORT perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 23:38
End of Day Share Price 2024/12/19 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Artivion, Inc. is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Raymond MyersBenchmark Company
Jason MillsCanaccord Genuity
Raymond MyersEmerging Growth Equities, Ltd.